Breaking News

Novavax, Serum Institute of India Enter COVID-19 Vax Mfg. Pact

Increases global production capacity for NVX-CoV2373 to over 2 billion doses annually as of 2021.

By: Contract Pharma

Contract Pharma Staff

Novavax, Inc. has amended its existing agreement with Serum Institute of India Private Ltd. (SIIPL) under which SIIPL will also manufacture the antigen component of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate. With this agreement, Novavax increases its manufacturing capacity of NVX-CoV2373 to over two billion doses annually, when all planned capacity has been brought online by mid-2021. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ recombinant protein nanoparticle technolog...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters